See more : Pontex Polyblend Co.,Ltd (8935.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Kobayashi Pharmaceutical Co., Ltd. (4967.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kobayashi Pharmaceutical Co., Ltd., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
- Gratomic Inc. (CB82.F) Income Statement Analysis – Financial Results
- Keiyo Co., Ltd. (8168.T) Income Statement Analysis – Financial Results
- Bull Will Co., Ltd. (6259.TWO) Income Statement Analysis – Financial Results
- Ash-Sharqiyah Development Co. (6060.SR) Income Statement Analysis – Financial Results
- Fintech Select Ltd. (SLXXF) Income Statement Analysis – Financial Results
Kobayashi Pharmaceutical Co., Ltd. (4967.T)
Industry: Household & Personal Products
Sector: Consumer Defensive
Website: https://www.kobayashi.co.jp
About Kobayashi Pharmaceutical Co., Ltd.
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells consumer products in Japan and internationally. The company provides products in the areas of healthcare, skincare, body warmer, and household. It also offers Ammeltz, a topical analgesic; Inochi no Haha, a women's health medicine; Shirt Coola, a summer cooling spray for cloths; Sarasaty lingerie soap; Bluelet Decoral, a toilet bowl cleaner and freshener; Nightmin Nasal Respiration Tape; Naishitol, a Chinese medicine; Eaude Muge, a medicated lotion for preventing acne; Itoyoji, a dental floss pick; BreathCare, an oral breath freshener capsule; Eybon, an eye wash; Netsusama sheet, a cooling gel sheet for forehead; and Sawaday, a toilet air freshener. Additionally, the company manufactures and sells pharmaceuticals, quasi-drugs, cosmetics, hygiene and paper products, health foods, and processed synthetic resin products; markets nutritional supplements and skin care products through sales promotional campaigns, such as advertising and direct mail; and sells skincare products, health foods, and other items through e-commerce channels. Further, it engages in transportation, real estate management, and advertising planning and production businesses. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 173.46B | 166.26B | 155.25B | 150.51B | 168.05B | 167.48B | 156.76B | 160.07B | 137.21B | 128.34B | 127.29B | 121.53B | 131.17B | 130.53B | 129.08B | 125.54B | 228.13B | 257.50B | 247.34B | 216.05B |
| Cost of Revenue | 77.08B | 73.93B | 66.48B | 65.25B | 64.71B | 64.36B | 61.24B | 66.23B | 57.52B | 54.72B | 54.19B | 51.73B | 54.64B | 55.89B | 57.19B | 56.86B | 146.95B | 172.78B | 167.72B | 144.26B |
| Gross Profit | 96.38B | 92.33B | 88.77B | 85.27B | 103.35B | 103.12B | 95.52B | 93.83B | 79.69B | 73.63B | 73.10B | 69.80B | 76.53B | 74.64B | 71.89B | 68.68B | 81.19B | 84.72B | 79.61B | 71.80B |
| Gross Profit Ratio | 55.56% | 55.53% | 57.18% | 56.65% | 61.50% | 61.57% | 60.94% | 58.62% | 58.08% | 57.37% | 57.43% | 57.43% | 58.35% | 57.18% | 55.69% | 54.71% | 35.59% | 32.90% | 32.19% | 33.23% |
| Research & Development | 9.00B | 8.33B | 7.52B | 7.34B | 7.11B | 7.03B | 7.24B | 5.49B | 5.79B | 5.29B | 4.93B | 4.54B | 4.39B | 4.07B | 3.96B | 3.36B | 2.81B | 2.48B | 2.38B | 2.12B |
| General & Administrative | 29.87B | 5.02B | 5.20B | 5.14B | 5.49B | 5.71B | 5.50B | 3.63B | 4.80B | 4.70B | 4.73B | 4.81B | 9.82B | 9.91B | 9.96B | 9.70B | 15.00B | 4.61B | 4.01B | 3.57B |
| Selling & Marketing | 27.74B | 26.58B | 26.59B | 26.01B | 42.27B | 42.03B | 39.34B | 61.01B | 31.28B | 26.72B | 26.52B | 25.65B | 22.20B | 20.48B | 20.32B | 19.92B | 19.33B | 18.85B | 17.66B | 16.21B |
| SG&A | 57.61B | 31.61B | 31.79B | 31.15B | 47.76B | 47.73B | 44.84B | 64.64B | 36.08B | 31.42B | 31.25B | 30.46B | 32.02B | 30.39B | 30.28B | 29.62B | 34.33B | 23.46B | 21.67B | 19.78B |
| Other Expenses | 3.98B | 25.72B | 23.39B | 20.83B | 22.11B | 22.06B | 976.00M | -604.00M | -86.00M | 404.00M | 515.00M | 415.00M | 250.00M | 158.00M | 40.00M | -226.00M | -3.02B | -3.22B | -2.18B | -2.00B |
| Operating Expenses | 70.60B | 65.66B | 62.70B | 59.32B | 76.99B | 76.82B | 72.59B | 70.73B | 61.43B | 55.70B | 54.97B | 52.89B | 50.34B | 49.50B | 48.16B | 46.29B | 54.49B | 45.60B | 43.49B | 39.38B |
| Cost & Expenses | 147.68B | 139.58B | 129.18B | 124.56B | 141.69B | 141.18B | 133.83B | 136.97B | 118.95B | 110.42B | 109.16B | 104.62B | 104.98B | 105.39B | 105.36B | 103.16B | 201.44B | 218.39B | 211.21B | 183.64B |
| Interest Income | 214.00M | 85.00M | 131.00M | 279.00M | 338.00M | 289.00M | 273.00M | 626.00M | 267.00M | 229.00M | 225.00M | 197.00M | 127.00M | 81.00M | 71.00M | 112.00M | 153.00M | 86.00M | 83.00M | 75.00M |
| Interest Expense | 29.00M | 18.00M | 18.00M | 21.00M | 20.00M | 35.00M | 38.00M | 0.00 | 33.00M | 22.00M | 18.00M | 24.00M | 43.00M | 60.00M | 88.00M | 123.00M | 70.00M | 70.00M | 93.00M | 86.00M |
| Depreciation & Amortization | 6.06B | 5.36B | 4.84B | 4.11B | 4.13B | 3.40B | 3.52B | 3.50B | 3.07B | 3.10B | 3.10B | 2.97B | 3.23B | 4.16B | 4.26B | 4.21B | 3.76B | 2.78B | 2.81B | 2.74B |
| EBITDA | 33.65B | 31.86B | 30.79B | 29.92B | 30.34B | 29.59B | 26.33B | 29.93B | 21.05B | 21.01B | 21.22B | 19.87B | 23.10B | 17.39B | 17.64B | 19.27B | 18.39B | 18.89B | 16.92B | 15.59B |
| EBITDA Ratio | 19.40% | 20.34% | 21.24% | 21.04% | 19.13% | 18.46% | 17.78% | 16.62% | 15.34% | 17.11% | 17.19% | 17.83% | 23.07% | 22.76% | 21.70% | 20.78% | 11.89% | 15.13% | 15.08% | 15.60% |
| Operating Income | 25.78B | 26.67B | 26.07B | 25.94B | 26.36B | 26.29B | 22.93B | 23.10B | 18.26B | 17.92B | 18.12B | 16.90B | 27.03B | 25.55B | 23.75B | 21.88B | 23.35B | 36.17B | 16.88B | 30.96B |
| Operating Income Ratio | 14.86% | 16.04% | 16.79% | 17.24% | 15.68% | 15.70% | 14.62% | 14.43% | 13.31% | 13.96% | 14.24% | 13.91% | 20.60% | 19.58% | 18.40% | 17.43% | 10.24% | 14.04% | 6.82% | 14.33% |
| Total Other Income/Expenses | 1.78B | 1.28B | 1.57B | 692.00M | 449.00M | -985.00M | -353.00M | 3.31B | 495.00M | 2.14B | 1.54B | 1.95B | 524.00M | -11.96B | -9.17B | -6.12B | -10.90B | -23.08B | -2.87B | -19.65B |
| Income Before Tax | 27.56B | 27.95B | 27.64B | 26.64B | 26.80B | 25.30B | 22.57B | 26.40B | 18.76B | 20.06B | 19.67B | 18.85B | 19.82B | 13.18B | 14.55B | 16.27B | 15.80B | 16.04B | 14.01B | 12.77B |
| Income Before Tax Ratio | 15.89% | 16.81% | 17.80% | 17.70% | 15.95% | 15.11% | 14.40% | 16.49% | 13.67% | 15.63% | 15.45% | 15.51% | 15.11% | 10.10% | 11.27% | 12.96% | 6.93% | 6.23% | 5.66% | 5.91% |
| Income Tax Expense | 7.22B | 7.93B | 7.92B | 7.43B | 7.67B | 7.28B | 6.71B | 7.39B | 5.30B | 7.61B | 7.36B | 6.68B | 8.10B | 3.84B | 5.30B | 7.42B | 7.30B | 7.86B | 6.28B | 5.97B |
| Net Income | 20.34B | 20.02B | 19.72B | 19.21B | 19.14B | 18.02B | 15.86B | 19.09B | 13.47B | 12.45B | 12.31B | 12.18B | 11.73B | 9.34B | 9.25B | 8.85B | 8.50B | 8.30B | 7.47B | 6.73B |
| Net Income Ratio | 11.73% | 12.04% | 12.70% | 12.76% | 11.39% | 10.76% | 10.12% | 11.93% | 9.81% | 9.70% | 9.67% | 10.02% | 8.94% | 7.15% | 7.17% | 7.05% | 3.73% | 3.22% | 3.02% | 3.11% |
| EPS | 268.16 | 259.61 | 252.35 | 245.70 | 244.07 | 228.04 | 201.31 | 238.82 | 165.55 | 152.72 | 150.28 | 148.68 | 143.18 | 113.98 | 112.93 | 107.93 | 102.80 | 100.38 | 90.06 | 80.85 |
| EPS Diluted | 268.16 | 259.58 | 252.35 | 245.70 | 244.07 | 227.95 | 201.03 | 238.47 | 165.30 | 152.72 | 150.28 | 148.68 | 143.18 | 113.98 | 112.93 | 107.90 | 102.71 | 100.23 | 89.50 | 80.85 |
| Weighted Avg Shares Out | 75.84M | 77.12M | 78.13M | 78.16M | 78.42M | 79.03M | 78.80M | 79.96M | 81.34M | 81.51M | 81.90M | 81.90M | 81.90M | 81.90M | 81.90M | 82.02M | 82.72M | 82.66M | 82.99M | 83.25M |
| Weighted Avg Shares Out (Dil) | 75.84M | 77.13M | 78.13M | 78.16M | 78.42M | 79.07M | 78.91M | 80.07M | 81.46M | 81.51M | 81.90M | 81.90M | 81.90M | 81.90M | 81.90M | 82.05M | 82.80M | 82.78M | 83.50M | 83.25M |
Source: https://incomestatements.info
Category: Stock Reports